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Abstract
We propose a computational simulation framework for describing cancer-therapeutic transport in the lung. A discrete
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the surrounding tissue are represented by a continuum approach for porous media. The system of equations of the coupled
discrete/continuum model contains terms that account for degradation processes of the therapeutic agent, the reduction of
the number of drug molecules by the lymphatic system and the interaction of the drug with the tissue cells. The
functionality of the coupled discrete/continuum model is demonstrated in example simulations using simplified pulmonary
vascular networks, which are designed to show-off the capabilities of the model rather than being physiologically accurate.
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Introduction
According to the World Health Organization, lung cancer kills
more people than any other type of cancer and is responsible for
1.4 million deaths worldwide yearly [1]. Often, drug treatments
employ a trial and error procedure to determine the most effective
dosage. A predictive mathematical model suitable to guide cancer-
therapeutic strategies is still lacking. There exist plenty of
publications about the modeling of fluid flow and delivery of
macromolecules in solid tumors, for example: [2], [3], [4], [5], [6]
and [7]. Further, there are several publications about blood flow
simulations in vascular networks, for example: [8], [9], [10], [11]
and [12]. While the application of these models is restricted to
tumor tissue or to vascular networks, the modeling concept
presented here is designed for the simulation of the fluid and drug
transport in the entire organ affected by the cancer: the
macrocirculation, the microcirculation, the tissue and the tumor.
A mathematical and a numerical model are developed that
describe the distribution of a targeted protein therapeutic within
the human lung for cancer therapy. The developed model concept
is based on these former publications about the flow and transport
processes in the macrocirculation, in the microcirculation and in
tumors. However, the coupling of a model for the macrocircula-
tion to a second model for the microcirculation and the
surrounding tissue and the representation of a whole organ
affected by a tumor are new.
To model the delivery of the therapeutic agent to the tumor
cells, the transport of the dissolved drug molecules within the
blood vessels, the flow across the vasculature walls into the
surrounding tissue, and the transport through the interstitial space
towards the tumor have to be described. If the tumor exceeds a
diameter of about three millimeters, tumor induced angiogenesis
will occur [13]. In this case, a direct transport of the therapeutic
agent via the blood vessels to the targeted cells is possible. The
model has to account for all aforementioned modes of transport.
The development of a mathematical and a numerical model that
are suitable to guide lung cancer therapeutic strategies is an
ambitious aim. This work does not claim to fully achieve this
ultimate goal. However, it is a first step towards it. This paper
focuses on the model development taking into account a number
of simplifying assumptions.
Figure 1 depicts the general concept of the model. It includes
the transport of the injected therapeutic agent through the
pulmonary circulation, the transition of the dissolved drug
molecules from the blood vessels into the tissue and the processes
occurring within the pulmonary tissue. The advection and
reaction of the blood-dissolved drug within the non-capillary part
of the vasculature is simulated using the previously presented
vascular graph model (VGM, see Section 1.1 and [9]). The
abundance of pulmonary capillaries (about 1800 capillary
segments per alveolus [14]) prevents the application of this
discrete approach to the capillary bed due to the high
computational cost incurred. Therefore, the flow, transport and
reaction processes within the capillary bed and the surrounding
tissue are described by the alveolus model instead, which is a
double-continuum approach (see Section 1.2). This approach is
based on two separated continua: the pulmonary tissue, and the
pulmonary capillaries that are coupled by transfer functions (see
Section 1.2.4). Thus, so-called upscaled nodes are inserted into the
computational lattice of the VGM, which represent the capillary
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flow simulations are corrected for the loss of therapeutic agent by
the transfer of the dissolved drug molecules through the capillary
walls into the tissue. The coupling of the alveolus model and the
vascular graph model is described in more detail in Section 1.3. An
alveolar cell carcinoma (cancer cells located in the alveolar tissue)
is modeled by introducing two kinds of upscaled nodes,
representing healthy and tumor tissue respectively. The concen-
tration distribution of a therapeutic agent administered via a bolus
injection is determined within the blood vessel network and the
surrounding tissue. Due to the different physiological properties in
a tumor, the drug concentration in the cancer region differs from
the one in the healthy pulmonary tissue. The simulation results,
which demonstrate the functionality of the coupled discrete/
continuum model, are presented in Section 2.4.
Methods
1.1 Vascular Graph Model (VGM)
The vascular graph model developed by Reichold and
coworkers [9] describes flow and transport processes in vascular
networks. Here it is used to compute the spatial and temporal
distribution of a therapeutic agent in the pulmonary arteries,
arterioles, venules and veins: a single-phase two-component (blood
and therapeutic agent) scenario. A brief summary of the VGM is
given and extensions/adaptations of the vascular graph model are
explained (for in-depth information see [9]). The VGM treats the
vasculature as a graph, i.e. a collection of vertices or nodes,
connected by edges (see Figure 2).
The nodes are the locations at which the vessels bifurcate or
end. The edges represent the blood vessels themselves. The
diameters of blood vessels vary along their length; typically they
are widest at the points of bifurcation. The VGM assigns a mean
diameter to each vessel and computes its conductance based on
this value. If two adjacent nodes (vertices that are connected by an
edge, e.g. node 1 and 2 in Figure 2) are at different blood pressure
values, blood flow will be induced between them. For every node i
of the vascular graph a continuity equation can be formulated:
L(ri,molVi)
Lt
z
X
j
FijzqfDCM~0, ð1Þ
where ri,mol, Vi are the blood density and the volume term at node
i, respectively. The mass flow rate through the pulmonary vessel
segment ij is denoted Fij and t designates the time. To a good
approximation, it may be assumed that blood is an incompressible
fluid. Therefore, ri,mol will remain constant unless the blood
composition changes significantly. The variable qfDCM mediates
the coupling of mass flow between the double-continuum model
and the vascular graph model. In particular, qfDCM is zero for
every node i of the vascular graph except for the so-called upscaled
nodes (for details see Section 1.3).
The mass flow rate between two nodes i and j depends on their
pressure difference Dpij, their geometrical distance Dzij in the
direction of gravitational acceleration g (assumed to act in negative
z-direction), the molar fluid density ri,mol, and the vessel resistance
Figure 1. General model concept. The vascular graph model describes the processes occurring in the arteries, arterioles, venules and veins. The
alveolus model, a double-continuum approach, represents the processes occurring in the capillary bed and the surrounding tissue (right image
according to Terese Winslow).
doi:10.1371/journal.pone.0031966.g001
Figure 2. Schematic representation of a vascular graph. A
collection of nodes i connected by edges ij.
doi:10.1371/journal.pone.0031966.g002
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Fij~
ri,mol DpijzrFgDzij
  
Rij
: ð2Þ
By inserting (2) into the continuity equation (1) for all vertices,
one obtains a linear system of equations whose solution yields the
vertex pressures. The flow in the pulmonary vasculature can then
be computed from the pressure field using (2). The system of
equations is linear due to the fact that the coupling variable qfDCM
is known at the time of solving the equations of the VGM (see
Section 1.3).
The distribution of blood in the lung is a function of the cardiac
output, gravity, and pulmonary vascular resistance. An average
human lung is about 30 cm long from the base (bottom of the
lung) to the apex (top of the lung). The pulmonary artery enters
each lung about midway between base and apex. Due to the
influence of gravity, most of the blood flows through the lower half
of the lung [15]. The model captures the gravitational effects, by
correcting the blood pressure value of each vertex by (rFgzi),
where zi is the distance of node i to the entry of the pulmonary
artery into the lung (see Figure 3). The difference in z of two nodes
i and j appears as Dzij in (2).
The resistance Rij to flow within a pulmonary vessel segment ij
is a result of the viscous forces, of the friction between the flowing
blood and the vessel wall, as well as of the friction between the
different blood components. Assuming that the flow can be
described by the Hagen-Poiseuille law (neglecting wall roughness),
the resistance can be written as:
Rij~
8mLij
r4
ijp
, ð3Þ
where m is the dynamic blood viscosity, Lij and rij are the length
and radius of the vessel segment, respectively. Blood is a
heterogeneous, non-Newtonian fluid that exhibits pseudoplastic
behavior [16]. The interactions of the different blood components,
which are the main origin of the blood properties, are accounted
for implicitly via a non-constant viscosity that depends mainly on
the vessel diameter and the hematocrit. In-vivo data reported by
Lipowsky and coworkers [17] are used to determine the
hematocrit in a vessel based on its diameter. In a second step,
the blood viscosity within the vessel is computed from the
hematocrit value using the relation derived by [18].
The volume Vi associated to a node i (as in (1)), is defined as the
sum of half the volume of all adjacent edges:
Vi~
X
j
1
2
AijLij
  
, ð4Þ
where Aij is the cross-sectional area of vessel ij. The diameter of
the blood vessels, and consequently the vessel volume, change
dynamically with the transmural pressure. The VGM takes this
effect into account by making the area of the cross-sections
pressure dependent. In this work, the values proposed by [19] are
used to describe the cross-sectional compliance LAij
  
= Lp ðÞ of the
different types of pulmonary vessels.
The transport of the dissolved drug molecules with the blood
stream is modeled by the subsequent equation:
L(ri,molxiVi)
Lt
z
X
j
Fijxijzri,degradationzqxDCM~0, ð5Þ
where xi is the mole fraction of the therapeutic agent within the
volume of node i, xij represents the mole fraction of dissolved drug
at the physical upstream node and qxDCM describes the coupling
of the double-continuum model to the vascular graph model,
taking into account the exchange of dissolved drug molecules
between the two models (see Section 1.3). The variable ri,degradation
is the sink term that accounts for the degradation processes of the
therapeutic agent such as micturition and metabolic transforma-
tion reactions [20]:
ri,degradation~ri,molkxi with k~
ln2
t1=2
, ð6Þ
where k denotes the first order rate constant of a drug
administered by a bolus injection and t1=2 is the half-life of the
administered drug.
1.2 Alveolus Model - A Double-Continuum Approach
The events occurring in the arteries, arterioles, veins and
venules are described by the vascular graph model. The flow,
transport, and reaction processes within the capillaries around a
single alveolus and the surrounding tissue are modeled using a
double-continuum approach (see Figure 1 and Figure 4). The
models of [7] and [5] also comprise a double porous medium using
Darcy’s law for the flow through the interstitium and the
vasculature. However, the alveolus model differs from these
previously presented models in that the coupling functions for the
flow and transport processes between the capillary bed and the
interstitium are the Starling equation (see (18)) and the
Stavermann-Kedem-Katchalsky equation (see (19)) respectively.
Both equations are traditionally used to describe microvascular
liquid transport in the lung [21]. Therefore they are ideally suited
as coupling functions for the alveolus model (see Section 1.2.4).
1.2.1 Double-Continuum Model (DCM) - The General
Model Concept. There are two main possibilities to describe
the flow and transport processes in a biological system: the
molecular approach and the continuum approach. The molecular
approach considers the movement of single molecules or particles
and their interactions under external influences. As the inner
diameter of an alveolus is in the order of 140 mm, the domain size
of the alveolus model is very large compared to the size of fluid
Figure 3. Gravity dependence of pulmonary blood flow.
doi:10.1371/journal.pone.0031966.g003
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particles required thus forbids the usage of a molecular approach.
Therefore, a continuum approach is chosen instead, to describe
the transport of the dissolved drug molecules through the
pulmonary capillaries and tissue, as well as the exchange
between compartments.
The structure of the biological system can also be considered
either in a discrete or continuous fashion. To make the transition
from a discrete to a continuum description, the concept of a
representative elementary volume (REV) is used [22]. The
pulmonary tissue and the capillary bed are both described as
two distinct continua. By means of volume averaging, the discrete
properties of the capillary bed and pulmonary tissue (such as the
size of the different cell types, pore-space geometry, capillary
characteristics) are represented by a continuum with new effective
parameters, e.g. porosity, tortuosity or permeability (for method-
ological details see [23]).
As shown on the left image in Figure 4, the pulmonary
capillaries are embedded in the pulmonary tissue. Flow, transport,
and reaction processes in both compartments are of interest - they
are, however, very different from each other. Therefore, the
capillary bed around a single alveolus and the surrounding tissue
are treated as two separate continua (see Figure 4). The flow and
transport processes between them, i.e. the exchange of fluid and
substances across the capillary walls into the pulmonary tissue and
vice versa, are honored via exchange terms, the so-called transfer
functions (see Section 1.2.4). The tissue continuum consists of cells,
fibers, amorphous ground substance and interstitial fluid. The
individual components are not densely packed. Therefore, a
fraction of the interstitial fluid can flow freely within the tissue.
Hence, the pulmonary tissue can be described with a porous
medium approach as it has already been done by [24]. About
1800 capillary segments, of 10 mm average length and 8 mm mean
diameter, enwrap a human alveolus [14]. The whole lung consists
of 300 million alveoli [25]. Therefore, a discrete modeling
approach would need to resolve 5:4:1011 capillary segments. To
avoid the high computational expense incurred, one can introduce
a capillary continuum instead, which represents the pulmonary
capillary bed around one alveolus as an averaged quantity. This
porous media concept requires effective parameters to be
determined, such as the permeability and porosity. The perme-
ability expresses the ability of a porous medium to transmit fluids.
In the case of the capillary continuum, this is determined by the
spatial distribution and the cross linking of the individual vessel
segments. The Hagen-Poiseuille law is a measure of the blood flow
velocity in the vessels [16] and relates it to the permeability (see
Section 2.3). The volume averaging over the capillary bed results
in a porosity value of one, i.e. the volume of the voids is equal to
the total volume.
In summary, the double-continuum approach treats pulmonary
tissue and capillary bed as two separate porous media continua.
The interactions between them are taken into account by transfer
functions.
1.2.2 Pulmonary Tissue Continuum. The phase moving
within the tissue continuum consists of two components, namely
the interstitial fluid and the therapeutic agent. It is assumed that
the fluid phase is incompressible. Thus, the movement of the
dissolved drug molecules in the interstitial tissue of the lung is
modeled using a single-phase two-component approach in a rigid,
porous medium. The influence of the respiratory movement on
the pulmonary tissue is not considered. The drug molecules are
completely miscible with the interstitial fluid. The interstitial fluid
is treated as a Newtonian fluid because it consists mainly of water.
It has a composition similar to blood plasma, which consists of 90
percent of water, nine percent organic, and one percent inorganic
substances that are dissolved in water [16]. With the additional
assumption that the flow within the tissue is creeping, the flow
velocity of the interstitial fluid can be described by Darcy’s law:
vf~{
K
m
+pzrFg+z ðÞ , ð7Þ
where vf is the Darcy velocity, K is the intrinsic permeability
tensor, rF is the mass density of the fluid, g is the gravitational
acceleration, and m is the dynamic viscosity of the fluid phase. The
calculation of the flow velocity through the interstitium with
Darcy’s law has been done previously, for example, by [2] or [26].
Due to the assumption of an incompressible fluid phase and a
constant tissue porosity, the temporal variation of the product of
porosity w and molar density rmol does not have to be considered
Figure 4. Explanation of the general concept of the double-continuum model.
doi:10.1371/journal.pone.0031966.g004
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equation is used:
+: fT rmolvf ðÞ zfTrlymph{qF~0: ð8Þ
Here, rmol is the molar density of the fluid and qF is the
coupling variable for the flow between the two continua. The
exact definition of the variable qF is given in Section 1.2.4. The
flow processes in the tissue and capillary continuum are calculated
in the same model domain. For this reason, a factor fT is
introduced to describe the volume fraction of tissue within the
model domain. The volume fraction of tissue fT and the capillary
volume fraction fC add up to unity:
fTzfC~1: ð9Þ
The exchange of fluid and dissolved components between the
tissue and capillary continuum is a surface related process.
Therefore, the intercompartmental exchange rate (and thus, the
coupling variable qF) depends, among others, on the surface area
of the capillaries per unit volume of tissue Avessel=Vtissue (see (18)).
It is therefore not explicitly corrected with the tissue volume
fraction fT.
At the arterial side of the capillary bed, about 0.5 percent of the
plasma that flows through the capillaries is filtered out into the
surrounding tissue. 90 percent of this extravasated fluid is
reabsorbed at the venous side of the capillary bed. The remaining
10 percent of the extravasated fluid is removed by the lymphatic
system from the interstitial space [16]. The lymphatic system
carries the excess of interstitial fluid, and, with it, dissolved and
suspended substances like macromolecules through the lymph
vessels and nodes into the great veins [27]. The influence of the
lymphatic system on the mass balance (8) is included by the sink
term rlymph [2]:
rlymph~Llymph
Alymph
Vtissue
pis{plymph
  
rmol, ð10Þ
where Llymph is the hydraulic conductivity of the lymphatic vessel
wall, Alymph is the surface area of the lymphatic vessels in the lung,
Vtissue is the unit volume of tissue, pis and plymph are the hydrostatic
pressure in the interstitial space and lymphatic system, respective-
ly. As there is no functional lymphatic system within a tumor [28],
the sink term rlymph is omitted in tumor tissue.
The transport of the dissolved therapeutic agent in the
pulmonary tissue is described by the following equation:
L(xisfT wrmol)
Lt
z+: fT rmolxisvf{fT wrmoltD+xis ðÞ
zfTrlymph{drugzfTradsorption{qT~0:
ð11Þ
The first term of (11) is the so-called storage term. It describes
the temporal variation of the product of tissue volume fraction fT,
porosity w, molar density rmol and mole fraction of the dissolved
component xis. The advective and diffusive transport of the
therapeutic agent within the tissue are expressed by the second
term. The diffusive transport of the drug depends on the aqueous
diffusion coefficient D of the therapeutic agent and the tortuosity t
of the tissue. The tortuosity characterizes the degree of sinuousness
of the routes of transport within the porous medium. The variable
qT is the transport coupling variable. It defines the amount of
dissolved drug molecules that is transported from the intravascular
space across the capillary wall into the tissue and vice versa (see
Section 1.2.4). The sink term rlymph{drug describes the reduction of
the number of drug molecules by the lymphatic system:
rlymph{drug~rlymphxis: ð12Þ
This sink term is defined in a similar way as the term for the
flow reduction by the lymphatic system (see (10)), except that the
mole fraction xis of the dissolved therapeutic agent is required in
addition.
The sink term radsorption [29] defines the interaction of the drug
molecules with the tumor cells. The ligand-receptor interaction
decreases the mole fraction of free flowing therapeutic agent:
radsorption~konxisrmol½R {koff ½R{L : ð13Þ
Here, ½R  is the receptor concentration, ½R{L  is the receptor-
ligand-complex concentration, kon is the kinetic constant for the
forward reaction, i.e. the binding of a ligand of the drug molecule
with a tumor cell receptor. The kinetic constant for the backward
reaction, i.e. the splitting of the chemical bond between the
therapeutic agent and the cell, is termed koff.
The sink term radsorption is only considered in tumor regions,
whereas rlymph is only included in regions of healthy pulmonary
tissue.
1.2.3 Pulmonary Capillary Bed Continuum. The capillary
continuum represents the pulmonary capillary bed around one
alveolus as an averaged quantity. The movement of the dissolved
drug molecules within the pulmonary capillaries is described with
a single-phase two-component approach. The incompressible fluid
phase consists of the two, completely miscible, components: blood
and therapeutic agent. According to [30], the velocity within the
single capillaries is constant in time. The capillaries may be treated
as rigid tubes [19] and due to the low Reynolds number within the
capillaries, about 0.003 according to [31], the flow is creeping.
Currently, the double-continuum model does not account for
variations in capillary morphology. It assumes that the diameter of
all pulmonary capillaries is constant (8 mm: the mean pulmonary
capillary diameter according to [14]). Consequently, a constant
viscosity value of 0.0021 Pa:s is assumed, which agrees with the
diameter and hematocrit dependent viscosity relation developed
by [18] that is used in the VGM.
As the capillary bed is treated as a porous media continuum,
Darcy’s law may be applied to determine the blood flow velocity.
This has been demonstrated by [32]. The method requires the
computation of the continuum’s intrinsic permeability tensor,
which depends mainly on the connectivity of the capillary
segments and their diameter. The intrinsic permeability tensor
of the capillary bed can be obtained analogous to the effective
conductance computation in [9]. The domain is divided into a
number of cuboid subvolumes. In order to compute the
permeability of one such subvolume in x-direction, the integral
mass flow Fx,REV is computed between the two faces normal to the
x-axis (using the VGM and the discrete capillary network).
Arbitrary (but different) pressure boundary conditions p1 and p2
are set at all vessel-endpoints crossing the two respective faces, and
no-flow boundary conditions are set at the remaining four faces
(see Figure 5). The permeability of the subvolume in x-direction
now reads:
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Fx,REV mLy,REV
Dp1{p2DAxz,REV
, ð14Þ
where Ly,REV is the length of the cuboid in y-direction and
Axz,REV is the cross-section of the considered REV parallel to the
x-axis. The permeabilities in y- and z-direction are computed
analogously. Repeating this method for each subvolume yields a
heterogeneous permeability field for the capillary bed around a
single alveolus. Ideally, one would use a high-resolution angiog-
raphy technique, such as synchrotron radiation X-ray tomograph-
ic microscopy (srXTM), to obtain the fully resolved capillary
network around an alveolus. Then, the above methodology can be
applied to determine a realistic intrinsic permeability tensor. As
high-resolution pulmonary angiography data are not available for
the present work, an artificial network is constructed instead.
According to [33], the alveolar capillaries form a hexagonal
network. Using the numerical values provided by [14], an artificial
capillary bed is constructed consisting of 1800 capillary segments,
each 8 mm in diameter and 10 mm long (see Figure 6). The
intrinsic permeability tensor of the pulmonary capillary bed is
obtained for the cuboid illustrated in Figure 6 by using the
aforementioned method. The dimensions of the cuboid in which
the hexagonal network of the capillaries is embedded depend on
the size of the model domain of the alveolus model and have an
influence on the permeability values (results shown in Section 2.3).
With the assumptions made at the beginning of Section 1.2.3
and given the intrinsic permeability tensor of the capillary
continuum, the flow of blood and dissolved therapeutic agent
can be described with the following continuity equation:
+: fCrmolvf ðÞ zqF~0: ð15Þ
The transport of the dissolved therapeutic agent is represented
by the subsequent equation:
L(xcfCrmol)
Lt
z+: fCrmolxcvf{fCrmoltD+xc ðÞ z
fCrdegradationzqT~0,
ð16Þ
where xc is the mole fraction of drug molecules dissolved in blood.
The degradation processes of the therapeutic agent are equal to
those described earlier for the vascular graph model, hence
rdegradation is given by (6). As the porosity w of the capillary
continuum is set to one, w does not appear in (15) and (16).
1.2.4 Coupling Functions for the Flow and Transport
Processes between the two Continua. The flow and
transport processes between tissue and capillary continuum are
described by the coupling functions qF and qT, based on the
transepithelial transport via transvascular pathways. Figure 7
illustrates the different cell morphologies, which can facilitate
transvascular transport, namely interendothelial clefts, fenestrae,
transcellular pores and vesicles. There are two main modes of
transport: transcellular and paracellular. The transcellular
pathway crosses the apical and basolateral membrane of the
endothelial cell and in most cases leads through a part of the
intercellular cleft. The paracellular way spans the entire length of
the intercellular cleft.
The transport across the capillary wall mainly depends on
relative pressure and concentration gradients (see Figure 8). The
hydrostatic and the oncotic pressures in the capillary and the
interstitial space determine the direction and the magnitude of
fluid flow between the two compartments. The oncotic pressure is
the sum of the colloid-osmotic pressure and an osmotic pressure
caused by the Gibbs-Donnan effect. The colloid-osmotic pressure
relates to the osmotic pressure caused by macromolecules. The
large anionic proteins in blood plasma cannot pass through the
capillary walls. Small cations are attracted, but not bound to the
large anionic proteins. Consequently, small anions will cross the
capillary walls away from the plasma proteins more rapidly than
small cations. This unequal distribution of permeable ions between
the intravascular and the interstitial space is called Gibbs-Donnan
Figure 5. Computation of the effective permeability of a REV.
Fixed pressures p1 and p2 set at all nodes crossing the left and right face
normal to x respectively (no-flow boundary condition at all nodes
crossing the other four faces). Effective permeability computed from
pressure gradient and integral mass flow FREV through the REV’s
capillary network (image modified from [9]).
doi:10.1371/journal.pone.0031966.g005
Figure 6. Determination of the permeability tensor for the
capillary continuum. Hexagonal mesh of pulmonary capillaries
embedded in a cuboid.
doi:10.1371/journal.pone.0031966.g006
Modeling Cancer-Therapeutic Transport in the Lung
PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e31966effect and influences also the flow of water across the semiperme-
able capillary wall.
The outflow of fluid from the capillaries into the interstitium
across the microvascular wall is called filtration or extravasation.
The inflow of fluid is termed reabsorption. The extravasated fluid
can either be reabsorbed by the same or a different capillary, or it
can leave the tissue via the lymphatic system [34]. The difference
of the hydrostatic pressures, also called transmural pressure, and
the oncotic pressures between the intravascular and the interstitial
space determine the fluid transport through the capillary wall:
peff~Dp{Dp~(pc{pis){(pc{pis): ð17Þ
peff is the effective filtration pressure, pc and pis are the hydrostatic
pressure in capillaries and interstitial space respectively. pc and pis
are the corresponding oncotic pressures. Solvent flux across the
microvascular wall is proportional to the effective filtration
pressure peff. According to Starling’s law, net fluid flow across a
vessel wall is given by [35]:
qF~rmolLp
Avessel
Vtissue
pc{pis{sp c{pis ðÞ ðÞ , ð18Þ
where Lp is the hydraulic conductivity of the vessel wall,
Avessel=Vtissue is the surface area of pulmonary capillaries per
unit volume of tissue. The capillary wall acts as a semipermeable
membrane and thus has a strong influence on the degree of
transvascular fluid flow. The reflection coefficient s describes
how well solute particles can move across the vessel wall. It can
vary from zero (i.e. no reflection, all particles pass the barrier) to
one (impermeable membrane). Equation (18) is used as the
coupling function qF for the fluid flow across the interface
between tissue and capillary continuum in the mass balance
equations (8) and (15). At the arterial side of the capillary bed, the
transmural pressure is higher than the osmotic pressure difference
between the plasma and interstitial fluid. Therefore, an outflow of
fluid is observed at these locations. Due to the flow resistance in
the blood vessels, the hydrostatic pressure in the capillaries
decreases along their length. At the venous side of the capillary
bed, the transmural pressure is equal to or often smaller than the
osmotic pressure difference. This is where reabsorption of water
takes place.
The Stavermann-Kedem-Katchalsky equation describes the
advective and diffusive transport of the therapeutic agent across
the microvascular wall [35]:
qT~rmolP
Avessel
Vtissue
xc{xis ðÞ zqF 1{sf
  
 x x, ð19Þ
where P is the permeability of the capillary wall. The solvent-drag
reflection coefficient sf describes the retardation of the therapeutic
agent as it passes through the vessel wall. The variable  x x represents
the mean mole fraction of dissolved therapeutic agent within the
pores of the capillary walls. According to [35], the mean mole
fraction of dissolved therapeutic agent within the pores can be
calculated by the logarithmic mean:  x x~ xc{xis ðÞ =ln(xc=xis).
Here,  x x is approximated by xc{xis ðÞ =2. Equation (19) is used as
the coupling function qT for the transport of the therapeutic agent
between tissue and capillary continuum in the component mass
balance equations (11) and (16).
1.3 Coupling the Alveolus Model to the Vascular Graph
Model
The vascular graph model and the alveolus model have been
described in Sections 1.1 and 1.2 respectively. This section gives
an overview of the approach used to couple the two models. The
coupling of VGM and DCM has the advantage that one obtains a
discrete representation of the vasculature where it is computa-
tionally affordable (i.e. at the non-capillary level) and a continuum
representation where a fully-resolved approach would be too
expensive (i.e. at the level of the capillary bed and its surrounding
tissue). The vascular graph model describes the flow and transport
of the therapeutic agent within the non-capillary pulmonary
vasculature. Each pre-capillary arteriole and each post-capillary
venule are connected via an upscaled edge to a so-called upscaled
node, representing the capillary bed of a single alveolus and its
associated tissue. These upscaled nodes are in turn described by
the double-continuum model. It is at these sites that the
administered drugs and blood plasma can leave the blood
compartment and enter the surrounding tissue. The double-
continuum model is used to compute the amount of therapeutic
agent and fluid leaving the blood stream and provides this
information to the VGM, where it is incorporated as additional
sink terms qxDCM and qfDCM for the upscaled nodes. This coupling
concept is illustrated in Figure 9. At each time step, the pressure
and the flow field for the whole vascular graph and the distribution
of the therapeutic agent in the graph are computed. Then, the
additional sink terms, also termed correction factors, are
recomputed separately for each upscaled node of the vascular
graph by calling the double-continuum model with the Python
subprocess module. The correction factors correspond to the
Figure 7. Paracellular and transcellular pathways [48].
doi:10.1371/journal.pone.0031966.g007
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compartment in a time dt, which is the duration of an (explicit)
time step of the VGM transport simulation. After the system of
equations of the DCM has been solved for every upscaled node of
the VGM to obtain the two coupling variables qxDCM and qfDCM
for the current time step of the VGM, the pressure and the flow
field of the vascular graph and the transport of the drug through
the graph are corrected by the calculated sink terms. Thus, the
DCM and the VGM are linked using sequential execution and
data transfer through the coupling variables qxDCM and qfDCM.
Initial and boundary conditions of the pressure, as well as the mole
fraction of the dissolved therapeutic agent are required for both
continua of the alveolus model, in order to solve for the additional
sink terms qxDCM and qfDCM. The pressure boundary conditions
for the capillary continuum are taken from the two VGM nodes
adjacent to the upscaled node. As the VGM provides no
information about pressure in the pulmonary tissue, the pressure
boundary condition for the tissue continuum is taken from
literature (see [34] and [28]). The two VGM nodes on the arterial
and on the venous side of the capillary bed provide the initial
condition of the therapeutic agent concentration in the capillary
bed. A linear relationship for the initial concentration in the
capillary bed continuum between the two nodes connected to the
upscaled node is taken. The initial drug concentration in the tissue
is assumed to be zero. At every further time step, the final
concentration of the previous time step is taken as initial condition.
Results
This section demonstrates how the coupled model described in
Section 1.3 can be applied to simulate therapeutic agent kinetics in
the lung. The computational grid is based on the literature values
given in [36] (see Table 1) and [37] (see Table 2). Horsfield and
coworkers studied the morphometry of the human pulmonary
arterial and venous trees, based on Strahler’s ordering system. The
Strahler algorithm defines the smallest non-capillary blood vessels
as order 1. If two vessels of the same order meet, the order number
of the confluent vessel will be increased by one. If a blood vessel of
order n meets another vessel of an order smaller than n, the order
of the confluent vessel will remain n ([38], see also Figure 10). The
Figure 8. Processes and forces of transvascular exchange [48].
doi:10.1371/journal.pone.0031966.g008
Figure 9. Concept for the coupling of the DCM to the VGM.
doi:10.1371/journal.pone.0031966.g009
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classification of pulmonary vessels is the dichotomous branching of
the pulmonary vascular tree [25].
2.1 Simulation Set-Up
A subset of the full pulmonary vasculature is chosen as the
domain for the simulation. Starting from Strahler order 4, a
dichotomous branching tree of arterioles is generated, leading to
21 pre-capillary arteries of order 1. These connect to as many
upscaled nodes, which in turn are connected to 21 post-capillary
venules of order 1. The veins dichotomously reunite until order 4
is reached (see Figure 10).
The diameters and lengths of the individual vessels are assigned
according to the measurement results of [36] and [37], as listed in
Tables 1 and Table 2. Three of the 21 upscaled nodes have been
assigned tumor properties, representing an alveolar cell carcino-
ma. These are the three upscaled nodes depicted by the blue
rectangles in Figure 10. The model domain of the DCM for a
healthy upscaled node represents an alveolus with its capillary bed
and surrounding tissue. It is constructed as a spherical shell with an
inner diameter of 140 mm (the mean diameter of a human alveolus
according to [14]) and an outer diameter of 364 mm (see
Figure 11). On the alveolar surface, the capillaries are arranged
in form of a hexagonal network with a few interspersed pentagonal
meshes to close the spherical surface [33]. In-between capillary
segments and above the capillary mesh, the pulmonary tissue is
located. The thickness of the tissue layer, 100 mm, is arbitrarily
chosen. The lumen of a pulmonary capillary is about 8 mm wide,
and the endothelial cell wall is approximately 2 mm thick
(according to [14] and [16]). The individual layers thus add up
to a total thickness of 112 mm. Therefore, the model domain has
an outer diameter of 364 mm. The model domain of the DCM for
a tumorous upscaled node is a sphere with a diameter of 364 mm.
It is assumed that the cancer cells have destroyed the alveolar
walls, and have penetrated into and filled the alveolus. The tumor
vasculature consists of vessels from the already existing network of
the host vasculature and new vessels resulting from the
angiogenesis response of the host vessels to the cancer cells [28].
There are no necrotic regions. It is assumed that the arterial input
to the capillary bed is on the left side of the alveolus, and the
venous drainage occurs at the right side (see Figure 11). Blood
cannot enter or leave the model domain via any other pathway.
According to [39], the pulmonary arterioles, also termed pre-
capillary vessels, give rise to the capillary networks and they
number between one and two per alveolus. Therefore, the
assumption of a single feeding arteriole and a single draining
venule is made.
This setup is meant to demonstrate the functionality of the
coupled model rather than being a realistic description of the
spatial and temporal distribution of a therapeutic agent within the
human lung for cancer therapy. Two simplifications are made.
First, the cross-sectional compliance, the pressure dependent
change of the cross-section of a vessel segment, is not considered in
this example. Second, the influence of the gravity on the blood
flow through the vessel segments is neglected. The data of [36] and
[37] only allow the generation of a two-dimensional graph. The
distance of each single vessel segment to the entrance of the
pulmonary artery into the lung cannot be determined.
2.2 Initial and Boundary Conditions
The system of equations of the vascular graph model and the
double-continuum model are solved for two primary variables: the
pressure p and the mole fraction of dissolved therapeutic agent x.
Initial and Dirichlet pressure boundary conditions are set at the
root arterial and root venous vertex. The numerical values chosen
are 1064 and 199.5 Pa respectively, taken from [15]. At the root
arterial vertex, the mole fraction of dissolved therapeutic agent x is
set to 1:1249:10{8. The initial and boundary conditions for the
upscaled nodes, where the double-continuum model’s system of
equations is solved, are automatically taken from the correspond-
ing adjacent VGM nodes, as is explained in Section 1.3.
Table 1. Model of the pulmonary arterial tree (according to
[36]).
order number of branches diameter in mm length in mm
17 1.000 30.000 90.50
16 3.000 14.830 32.00
15 8.000 8.060 10.90
14 2:000:101 5.820 20.70
13 6:600:101 3.650 17.90
12 2:030:102 2.090 10.50
11 6:750:102 1.330 6.60
10 2:290:103 0.850 4.69
9 6:062:103 0.525 3.16
8 1:877:104 0.351 2.10
7 5:809:104 0.224 1.38
6 1:798:105 0.138 0.91
5 5:672:105 0.086 0.65
4 1:789:106 0.054 0.44
3 5:641:106 0.034 0.29
2 2:028:107 0.021 0.20
1 7:292:107 0.013 0.13
doi:10.1371/journal.pone.0031966.t001
Table 2. Model of the pulmonary venous tree (according to
[37]).
order number of branches diameter in mm length in mm
15 4.000 13.88 36.7
14 1:400:101 5.23 39.0
13 5:3:101 2.90 25.4
12 1:580:102 1.90 18.5
11 4:960:102 1.21 11.0
10 1:842:103 0.61 3.20
9 7:546:103 0.39 2,54
8 2:3843:104 0.22 1.98
7 7:3869:104 0.14 1.34
6 2:33093:105 0.096 0.910
5 7:35516:105 0.064 0.617
4 2:320897:106 0.043 0.418
3 7:323513:106 0.029 0.283
2 2:3109101:107 0.019 0.192
1 7:2920000:107 0.013 0.130
doi:10.1371/journal.pone.0031966.t002
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The results, shown in Section 2.4, are based on the parameter
values presented here. The vascular graph model requires the
diametersandlengthsofthevesselsegmentsthatmakeupthevascular
graph. The numerical values of these vessel properties are taken from
Table 1 and Table 2. Table 3 gives an overview of the parameters
used in the alveolus model for the healthy and the tumorous case.
Most variables are taken from literature. However, for some
parameters no suitable values could be found. For most parameters,
Table 3 shows the ranges of the used parameters given in literature.
As it has already been discussed in Section 1.2.3, the processes
in the alveolar capillary bed are described with a porous media
approach. The results of the permeability field calculation for a
healthy upscaled node are shown in Table 4. The cuboid used to
compute the permeability tensor has an edge length of 364 mm in
x- and y-direction and extends 112 mm in z-direction. The
dimensions of the cuboid depend on the model domain of the
DCM - a spherical shell with an inner diameter of 140 mm and an
outer diameter of 364 mm. The permeability in z-direction is zero
because the capillary bed forms a two-dimensional hexagonal
mesh in the xy-plane (see Figure 6). As the capillary bed enwraps
the spherical alveolus, it is necessary to transform the permeability
tensor computed for the cuboid KC into the coordinate system of
the model domain, a spherical shell, to obtain the permeability
tensor of the capillary bed KCB. This is done by setting:
KCB~RTKCR, ð20Þ
where R is the three-dimensional rotation matrix and RT is its
transpose. The result of this transformation is the symmetric,
Figure 10. Visualization of the vascular graph coupled to the DCM. The black lines represent the blood vessels, which form the unstructured
grid of the VGM. The red nodes and the blue rectangles symbolize the capillary bed and pulmonary tissue around an alveolus, which are simulated
using the DCM. The red nodes are the healthy upscaled nodes and the blue rectangles are the tumorous ones. The blood vessels above/below the
alveoli are arteries/veins of the order one to four, with a morphology according to Table 1 and Table 2 respectively. The numbers indicate the
classification of the vessel segments according to the Strahler ordering system.
doi:10.1371/journal.pone.0031966.g010
Figure 11. Left. Model domain of the alveolus model for an healthy upscaled node consisting of a spherical shell with an inner diameter of 140 mm
and an outer diameter of 364 mm (image modified from Weibel (1991) [33]). Right. Different kind of structures comprised by the model domain of
the DCM.
doi:10.1371/journal.pone.0031966.g011
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parameter symbol value parameter range
tissue continuum
diffusion coefficient
3 D [m2 
s] 5:12:10{14[see text] -
dynamic viscosity
1 m [Pas] 1:2:10{3 [49] 1:16:10{3–1:35:10{3 [50]
hydraulic conductivity of lymphatic vessel wall
2 Llymph [m=Pas] n: 1:9:10{12[see text] -
initial receptor concentration ½R0  [mol
 
m3] t: 1:7:10{5[see text] -
kinetic constant: forward reaction kon [m3(mols)]t : 1:102[see text] -
kinetic constant: backward reaction koff [1=s] t: 1:10{3[see text] -
interstitial fluid pressure p [Pa]n : 21064 [34] -
t: 133 133–3591 [28]
lymphatic pressure
2 plymph [Pa]n : 21200[see text] -
mass density
1 rF [kg
 
m3] 1030 [51] -
molar density
1 rmol [mol
 
m3] 303.5 [16] -
permeability K [m2]n : 4:4:10{18 2:8:10{18–7:9:10{18 [52]
t: 2:1:10{17 3:5:10{18 [52]–3:7:10{17 [2]
porosity w [-] n: 0.13 0.13–0.3 [2]
t: 0.27 0.21–0.37 [53]
surface area of lymph vessels per unit volume of tissue
2 Alymph
Vtissue
[1=m]
n: 3.0 [see text] -
tortuosity t [-] n: 0.28 [54] -
t: 0.71 0.60–0.84 [55]
volume fraction of tissue fT [-] n: 0.9[see text] -
t: 0.8 0.80–0.99 [2]
capillary continuum
capillary volume fraction fC [-] n: 0.1[see text] -
t: 0.2 0.01–0.20 [2]
diffusion coefficient
3 D [m2 
s] 2:93:10{14[see text] -
dynamic viscosity
1 m [Pas] 0.0021 [18] -
half-life of therapeutic agent t1=2 [s] 21600[see text] -
mass density
1 rF [kg
 
m3] 1050 1040–1060 [31]
molar density
1 rmol [mol
 
m3] 284 [16] -
permeability K [m2] n: see Table 4 -
t: 1:25:10{11[see text] -
porosity
3 w [-] 1[see text] -
tortuosity
3 t [-] 1[see text] -
transfer equations
capillary oncotic pressure pc [Pa] n: 3724 [34] -
t: 2660 [2], [43] -
diffusive permeability P [m=s] n: 2:2:10{9 7:3:10{10–1:9:10{8 [2]
t: 1:73:10{8 5:7:10{9–1:5:10{7 [2]
hydraulic conductivity Lp [m=Pas] n: 2:71:10{12 [2] 2:5:10{12–5:0:10{11 [56]
t: 2:11:10{11 [2] 7:3:10{14–3:6:10{11 [57]
interstitial oncotic pressure pis [Pa] n: 1862 [34] -
t: 1995 [2] -
molar density
1 rmol [mol
 
m3] 293.75[see text] -
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permeability tensor from the coordinate system of the cuboid to
the coordinate system of the spherical shell, the permeability
values normal to the surface of the shell become zero. Solid tumors
are characterized by many tortuous vessels, shunts, vascular loops,
irregular intervascular distances and large avascular areas [40].
Hence, the capillary bed for the three tumorous upscaled nodes is
not represented by a hexagonal meshwork. Due to the lack of high
resolution angiography data of alveolar cell carcinoma, the
Hagen-Poiseuille equation is used to estimate the permeability K
of the tumorous capillary bed. Comparing the Hagen-Poiseuille
equation with Darcy’s law (see (7)), a relationship for the
permeability K of the capillary bed of the tumor can be found:
K~
r2
c
8
, ð21Þ
where rc is the mean capillary radius of a tumor vessel. According
to [41], rc is set to 10 mm. The diffusion coefficient D of the
injected therapeutic agent depends strongly on the size of the
considered drug molecules. For drug molecules dissolved in blood
and interstitial fluid, it can be calculated using the Stokes-Einstein-
Equation:
D~
RT
NA6pmr
, ð22Þ
where R is the gas constant and NA is the Avogadro number. For
the body temperature T a value of 310.15 Kelvin is assumed. The
radius r of the drug molecules is approximated by a mean value of
3.7 nm. The value for the dynamic viscosity m of blood and of the
interstitial fluid are assigned as listed in Table 3. The balance
equations (8) and (11) of the tissue continuum contain a sink term
that considers the influence of the lymphatic system on the amount
of interstitial fluid and drug molecules within the tissue. Lymph
formation occurs when the lymphatic pressure plymph drops below
the pressure in the interstitial space pis (see (10) and (12)).
However, the pulmonary lymphatic pressure has not yet been
measured. Experiments have merely shown that the pulmonary
lymphatic pressure is at least as low as the local interstitial pressure
[42]. The values for Llymph, Alymph=Vtissue and plymph are based on
our assumptions. In the case of a tumorous upscaled node, the
transport equations of the tissue continuum contain a sink term
that considers the interaction of the drug molecules with the
cancer cells. The values for the two kinetic constants kon and koff
and for the concentration of initially free receptors on the cell
surface ½R0  are based on experimental data studying the binding
effect of scFv225scTRAIL fusion proteins to H460 cells (unpub-
lished data of M. Doszczak and P. Scheurich, Institute of Cell
Biology and Immunology - University of Stuttgart). For the half-
life of the drug molecules t1=2, an arbitrary value is used. If the
model is applied to a specific drug administered by bolus injection,
the properties of that particular therapeutic agent need to be
implemented. Further, no specific value for the molar density of
blood could be found. The value listed in Table 3 is only valid for
blood plasma. The values for the porosity w and the tortuosity t of
the capillary continuum are based on the considerations in Section
1.2.3. In case of a healthy upscaled node, the chosen values for the
volume fraction of tissue fT and for the capillary volume fraction
fC of the model domain are chosen as follows. According to [43],
the vascular volume fraction in a 12 mm thick section of the
alveolar surface is 0.9. Above this layer, we assume a 100 mm thick
layer of pulmonary tissue that is not vascularized. Therefore, the
overall volume fractions in the entire model domain (representing
a healthy upscaled node) are fT~0:9 and fC~0:1 for tissue and
capillaries respectively. The transfer equations that couple flow
and transport processes between tissue and capillary continuum
contain the molar density of the exchanged fluid. In the tissue
continuum the considered fluid is the interstitial fluid and in the
capillary continuum it is blood. Therefore, the molar density used
in the transfer equations is the arithmetic mean of the molar
densities of these two fluids. Additionally, the capillary surface area
per unit volume of tissue Avessel=Vtissue is included in the transfer
equations. For the healthy upscaled nodes, this value is calculated
based on the geometry of the model domain (a spherical shell):
Avessel
Vtissue
~
Nvessel2rvesselplvessel
4
3
p r3
outersphere{r3
innersphere
   : ð23Þ
Nvessel stands for the number of vessels inside the model domain.
rvessel and lvessel are the radius and length of the capillary segments.
Table 3. Cont.
parameter symbol value parameter range
osmotic reflection coefficient
3 s [-] 0.8 [42] -
solvent-drag reflection coefficient sf [-] n: 0.91 [2] -
t: 0.82 [2] -
surface area of capillaries per unit volume of tissue Avessel
Vtissue
[1=m] n: 1:9:104[see text] -
t: 2:0:104 [2] -
1Fluid properties do not change in a tumor.
2There is no lymphatic system in a tumor.
3The healthy parameter value is also taken for the tumor area.
t: tumor tissue; n: normal tissue.
doi:10.1371/journal.pone.0031966.t003
Table 4. Calculation of permeability field of the cuboid
shown in Figure 6.
Kx [(mm)
2] Ky [(mm)
2] Kz [(mm)
2]
cuboid with hexagonal
network
0.15 0.22 0.00
doi:10.1371/journal.pone.0031966.t004
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sphere respectively.
2.4 Simulating the Flow and Transport Processes of a
Therapeutic Agent within the Lung
The spatio-temporal distribution of a therapeutic agent in the
lung is studied numerically using a subset of the full pulmonary
vasculature (see Figure 10). The linear system of equations of the
VGM is numerically solved using a finite difference method for the
spatial discretization and an explicit Euler scheme for the time
discretization. The system of equations of the VGM is solved for
the two primary variables, the pressure p and the mole fraction of
dissolved therapeutic agent x, using a decoupled scheme. First,
Equation (1) is used to compute the pressure field in the vascular
graph. Then, the distribution of the dissolved drug can be
determined using Equation (5). As a consequence of the explicit
time discretization, the Courant-Friedrichs-Lewy (CFL) condition
is applied to guarantee the stability and the convergence of the
solution. The transport equation (5) is a hyperbolic partial
differential equation. Therefore, a first-order upwind scheme is
applied for the discretization of the advection term. The vascular
graph model is programmed in Python, performance-critical parts
are written as C-extensions using Cython. The coupling of the
DCM to the VGM is realized with the Python subprocess module.
The non-linear system of equations of the DCM is numerically
solved using a fully upwind vertex centered finite volume method,
also called fully upwind box method (see [44]), for the spatial
discretization and an implicit Euler scheme for the time
discretization. The system of equations of the alveolus model is
solved for the four primary variables, the pressures pis and pc and
the mole fraction of dissolved therapeutic agent in the tissue
continuum xis and in the capillary continuum xc, using a fully
coupled scheme. Equation (8) and Equation (15) are used to
compute the pressure fields in the pulmonary tissue and in the
capillaries. Then, the distribution of the dissolved drug in the two
continua can be determined using Equation (11) and Equation 16).
The coupling of the two continua is realized by the exchange
terms qxDCM and qfDCM and numerically implemented as
additional source/sink terms. The numerical model of the alveolus
model is implemented into the open-source porous media
simulator DuMux, [45], which is based on the Distributed and
Unified Numerics Environment DUNE.
The simulation is performed as detailed in the previous sections.
Initially, the pressure and flow fields of the vascular graph are
computed. Then, a therapeutic agent is introduced at the arterial
root vertex. The dissolved drug molecules are advected through
the vasculature. At the alveoli, a fraction of the blood plasma and
therapeutic agent migrate into the tissue. The exchange rates and
phamacokinetics of this process differ between healthy and
tumorous alveoli. Due to the intercompartmental exchange, the
pressure and flow field of the vascular graph have to be
recomputed at each time step.
Figure 12 depicts the pressure field and the concentration of the
drug molecules at different times during the simulation. The two
vessel segments with a Strahler order of 4 have the smallest vessel
resistance and therefore the pressure drop is lowest along these
segments of the graph (see Figure 12 (a)). In the vessel segments
with a Strahler order of 1, the vessel resistance is largest and thus
the pressure drop is highest. The effective vessel resistance of a
tumorous upscaled node is smaller than the vessel resistance of a
healthy upscaled node. Therefore, the pressure gradient along the
two edges that are connected with a tumorous upscaled node is
smaller (see Figure 12 (a)). The dissolved therapeutic agent is
irregularly distributed in the vascular graph (see Figure 12 (c)). The
total amount of therapeutic agent that leaves the blood stream at
the tumorous upscaled nodes is higher compared to the healthy
upscaled nodes (see Figure 12 (c)). The maximum value for the
drug concentration in the tissue is also higher for a tumorous
upscaled node than for a healthy one (compare Figure 13 (d) with
Figure 14 (d)). This depends on the different pressure fields in the
blood and tissue continuum for the two kinds of upscaled nodes as
well as on the higher diffusive permeability and hydraulic
conductivity of tumor vessels and the increased number of blood
vessels per unit volume of tissue in the tumor region.
Figure 12. Results of the vascular graph model. (a) Pressure
distribution [Pa]. (b) A therapeutic agent is introduced at the arterial
root vertex. Drug distribution [mol=mol] after one time step. (c) Drug
distribution [mol=mol] after 11 seconds.
doi:10.1371/journal.pone.0031966.g012
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within the two continua of the double-continuum model for a
single healthy upscaled node. For the visualization of the results of
a healthy upscaled node, the red node situated in the leftmost
position in Figure 10 is chosen. Figure 13 (a) and (b) show a cross-
section through the model domain representing the pressure and
mole fraction distribution for the capillary continuum. The
pressures at the left side and the right side of the capillary
continuum are equal to the pressures at the two adjacent nodes
connected to the upscaled node. The administered therapeutic
agent is distributed within the capillary bed as shown in Figure 13
(b). Figure 13 (c) and (d) show a cross-section through the model
domain representing the pressure and mole fraction distribution
for the pulmonary tissue continuum. According to [34], the
interstitial fluid pressure in the human pulmonary tissue is
21064 Pa. Due to filtration and reabsorption processes across
the capillary walls, the pressure slightly changes within the model
domain (see Figure 13 (c)). The therapeutic agent is distributed
within the pulmonary tissue corresponding to the pressure
gradients in the pulmonary tissue. However, the amount of active
ingredient is about three orders smaller compared to the capillary
continuum (see Figure 13 (d)).
Figure 14 depicts the pressure and mole fraction distribution
within the two continua of the double-continuum model for a
tumorous upscaled node. In Figure 14 the results of the middle
tumorousupscalednodeareshown.Forthetumorousupscalednode
other parameters are used than for the healthy upscaled node (see
Table3).A further differenceisthattheflow and transport equations
of the DCM for the tumorous upscaled node have no sink terms for
describing the effects of the lymphatic system. The sink term
radsorption in (11) is only considered for the tumorous case. Due to the
pressure distribution in the vascular graph (see Figure 12 (a)), the
pressure boundary conditions for the capillary bed continuum of the
healthy and the tumorous upscaled node are not the same (see
Figure13(a)andFigure14(a)).Thedifferingpermeabilityfieldsused
for the two kinds of upscaled nodes are a further reason for the
different pressure fields in the capillary bed continuum of the
tumorous upscaled node and the healthy upscaled node. The
administered therapeutic agent is distributed within the capillary bed
as shown in Figure 14 (b). Figure 14 (c) and (d) show a cross-section
through the model domain representing the pressure and mole
fraction distribution for the tumorous pulmonary tissue continuum.
According to [28], tumors exhibit high interstitial fluid pressures.
Therefore, a Dirichlet pressure boundary condition of 133 Pa is set
for the tissue continuum. Due to the lack of a functional lymphatic
system and a higher filtration of fluid from the capillaries into the
tumor tissue, the interstitial fluid pressure increases further in the
model domain (see Figure 14(c)). However, a certain amountoffluid
is reabsorbed at the venous ends of the capillaries. Due to the higher
vascular permeability and hydraulic conductivity of tumors [28] and
the presence of blood vessels in the whole model domain, the drug
molecules are spread in the entire tumor tissue (see Figure 14 (d)).
Discussion
The model presented in this work describes the flow, transport
and reaction processes of a therapeutic agent in the pulmonary
Figure 13. Results for a healthy alveolus (leftmost red node in Figure 10), at the final time step of the simulation. (a) Pressure
distribution within the pulmonary capillary bed continuum [Pa]. (b) Drug distribution [mol=mol] within the pulmonary capillary bed continuum. (c)
Pressure distribution within the pulmonary tissue continuum [Pa]. (d) Drug distribution [mol=mol] within the pulmonary tissue continuum.
doi:10.1371/journal.pone.0031966.g013
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It accounts for the influence of micturition and metabolic
transformation reactions on the agent concentration. Moreover,
the role of the lymphatic system as well as the binding of the drug
molecules to tumor cells are captured. As such, the model can
predict the distribution of a drug administered by continuous bolus
injection for the therapy of alveolar cell carcinoma.
In order to guide cancer-therapeutic strategies, however, several
important extensions need to be made. The reaction of cancer
cells to therapeutic agent binding, the proapoptotic signaling
cascade, and the interactions between the individual tumor cells
have to be modeled in addition. The model consists of two
interconnected sub-models, namely the vascular graph model that
describes the processes occurring at the non-capillary level, and
the alveolus model that simulates the processes within the alveolar
capillary bed and tissue (both in the healthy and disease state). The
focus of the model is on predicting the spatiotemporal distribution
of therapeutic agents. Angiogenesis and tumor growth are
currently not considered. However, these effects occur at
timescales that are much larger than those of drug transport and
adsorption [2]. Therefore, one can use the model as described in
this manuscript to compute the evolution of blood flow and drug
distribution as a succession of steady states. After several hours, the
vascular and the tissue configuration in the cancerous region
change slightly, according to the progression of tumor growth and
angiogenesis, which remain to be implemented. The numerical
simulation concept presented here, is a first step towards a
predictive mathematical and numerical model suitable to guide
pulmonary cancer-therapeutic strategies. The concept is chiefly
based on theoretical considerations and thus requires validation by
comparison with experimental results. Future work will include the
acquisition of high-resolution angiography data of the pulmonary
circulation (e.g. via srXTM) to generate a realistic vascular graph.
A fully resolved capillary bed around a single alveolus and of the
alveolar cell carcinoma are the prerequisite to determining the
accurate permeability tensor of the capillary continuum in the case
of a healthy or a tumorous upscaled node. Once these data are
available, the simulation results can be compared with existing
measurements to verify the developed numerical model.
As blood is a heterogeneous, non-Newtonian fluid that exhibits
pseudoplastic behavior, the VGM determines the blood viscosity
within the vessel segments of the considered vascular graph from
the hematocrit value using the relation derived by [18]. Currently,
the DCM does not account for variations in the capillary
morphology. It is assumed that all capillaries have the same
physical properties. Consequently, a constant viscosity value is
taken. According to [46], models treating capillaries as a spatial
continuum with a given permeability which is based on the local
morphology of the capillary network neglect the role of the red
blood cells on the flow and transport processes through this
network of capillaries. As it is already stated in the paragraph
above, high resolution angiography data are required for the
pulmonary capillary bed and the alveolar cell carcinoma to
determine the intrinsic permeability tensor for Darcy’s law. The
approach for determining the intrinsic permeability tensor from
high resolution angiography data should be extended by the
Figure 14. Results for a tumor alveolus (middle blue rectangle in Figure 10), at the final time step of the simulation. (a) Pressure
distribution within the pulmonary capillary bed continuum [Pa]. (b) Drug distribution [mol=mol] within the pulmonary capillary bed continuum. (c)
Pressure distribution within the pulmonary tissue continuum [Pa]. (d) Drug distribution [mol=mol] within the pulmonary tissue continuum.
doi:10.1371/journal.pone.0031966.g014
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presented in [46] and [47] to account for the influence of the red
blood cells on the vessel resistance of capillaries.
Until now, the simplifying assumption of a non-pulsating flow
through the vessel segments of the vascular graph and the capillary
bed of the alveolus model is made. However, the arterial blood
pressure rises and falls due to the phases of the cardiac cycle [15].
In the future, the vascular graph model and the double-continuum
model should include the cyclic pressure changes in the blood
vessels.
It is our goal to further improve the accuracy of the model by
the extensions outlined above such that the model can be of high
clinical value. However, a model which strives to be of clinical
value requires a thorough sensitivity analysis. In our particular
case, the sensitivity analysis needs to determine how the
uncertainty in the model parameters affects the primary variables
of VGM and DCM, namely the pressure and the mole fraction of
dissolved therapeutic agent. In other words, the sensitivity analysis
needs to identify the most important influences on the coupled
discrete/continuum model for describing cancer therapeutic
transport in the lung.
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